Inventor · New York, NY, US

Stewart Shuman

31Patents
8h-index
19Co-inventors
72Inventor score

Filing activity: Dec 19, 1994 → Dec 21, 2022

Most-cited inventions

PatentTitleAreaCited byStatus
US5766891A Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase Chemistry; Metallurgy 85 Expired
US6916632B2 Methods and reagents for molecular cloning Chemistry; Metallurgy 48 Expired
US6548277B1 Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase Chemistry; Metallurgy 20 Expired
US6232070A Pharmacological targeting of mRNA cap formation Chemistry; Metallurgy 14 Expired
US6653106B1 Topoisomerase-based ligation and cloning methods Chemistry; Metallurgy 13 Expired
US10736962B2 Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors Emerging Cross-Sectional Technologies 13 Active
US10548930B2 Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors Chemistry; Metallurgy 13 Active
US7026141B2 Topoisomerase-based reagents and methods for molecular cloning Chemistry; Metallurgy 10 Expired
US10639366B2 Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors Chemistry; Metallurgy 8 Active
US10512662B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 4 Active
US7550295B2 Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase Chemistry; Metallurgy 2 Expired
US11285209B2 Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors Emerging Cross-Sectional Technologies 2 Active
US6107040A Pharmacological targeting of mRNA cap formation Chemistry; Metallurgy 2 Expired
US7662556B2 Covalent joining of DNA to RNA by vaccinia topoisomerase and uses thereof Chemistry; Metallurgy 2 Expired
US11253560B2 Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors Chemistry; Metallurgy 2 Active
US6420163B1 Pharmacological targeting of mRNA cap formation Chemistry; Metallurgy 1 Expired
US7528241B2 Methods and reagents for molecular cloning Chemistry; Metallurgy 1 Expired
US6451583B1 Pharmacological targeting of mRNA cap formation for treatment of parasitic infections Emerging Cross-Sectional Technologies 1 Expired
US11986503B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 1 Active
US11541087B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 1 Active
US8192932B2 Covalent joining of DNA strands to RNA strands catalyzed by vaccinia topoisomerase Chemistry; Metallurgy 1 Active
US10765711B2 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy Chemistry; Metallurgy 1 Active
US12036279B2 Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors Emerging Cross-Sectional Technologies 1 Active
US8551739B2 Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase Chemistry; Metallurgy 0 Active
US12252702B2 Recombinant poxviruses for cancer immunotherapy Emerging Cross-Sectional Technologies 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.